Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) expanded its collaboration with SRL to enable local BRACAnalysis Diagnostic System testing in Japan, subject to regulatory approval. Under the expanded agreement, SRL will perform all laboratory processing locally, while Myriad will continue providing genetic interpretation services.
Myriad expects eliminating shipment of patient samples to its Utah laboratory for sequencing to improve testing efficiency and shorten turnaround times. Japan is the company's largest international market. The company expects the local capabilities could support additional precision medicine and companion diagnostic offerings in the future. With SRL, Myriad intends to pursue additional regulatory approvals and reimbursement to expand its ability to serve Japan's health care system.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Expanded SRL agreement provides for local laboratory processing in Japan, with Myriad retaining genetic interpretation services.
- Minor point. Forward-looking: it has not happened yet and may not happen.Local testing is expected to improve efficiency and shorten turnaround times by eliminating sample shipments to Utah.
- Minor point. Forward-looking: it has not happened yet and may not happen.Future offerings could be supported by local capabilities; Myriad intends to pursue additional approvals and reimbursement with SRL.
Negative
- Moderate pointRegulatory approval remains a condition for enabling local BRACAnalysis Diagnostic System testing in Japan.
Key Terms
companion diagnostic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Enhanced partnership expected to strengthen Myriad's position in its largest international market
SALT LAKE CITY, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces an expansion of its collaboration with SRL, one of the Japan's largest and leading clinical laboratory testing companies, to enable local testing for BRACAnalysis® Diagnostic System in Japan, subject to regulatory approval. The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.
Local capabilities designed to support growth and future expansion
Under the expanded agreement, SRL will perform all laboratory wet work for BRACAnalysis Diagnostic System locally in Japan, while Myriad will continue to provide genetic interpretation services. Because this approach eliminates the need to ship patient samples to Myriad’s central laboratory in Utah for sequencing, it is expected to improve testing efficiency and shorten sample turn-around-time for the clinician and the patient.
The expanded collaboration is also expected to establish local capabilities that could support additional precision medicine and companion diagnostic offerings in the future. In partnership with SRL, Myriad intends to pursue additional regulatory approvals and reimbursement to strengthen the company’s ability to serve the Japanese health care system.
“Expanding our collaboration with SRL strengthens our ability to serve patients and health care providers in Japan while creating a platform for long-term profitable growth,” said Vishal Sikri, Executive Vice President, Commercial, Myriad Genetics. “Enabling local testing of Myriad’s genetic tests is expected to improve the testing experience and position us to bring additional precision medicine and companion diagnostic offerings to the Japanese market.”
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.
About SRL, Inc.
SRL, a member of the H.U. Group, is a leading company in the clinical laboratory testing industry in Japan. Leveraging its advanced testing technologies and a nationwide network, SRL provides high-quality laboratory testing services primarily to medical institutions and research organizations. In particular, SRL has established strong expertise in esoteric testing and cutting-edge genetic testing, such as oncology and infectious diseases. Supported by decades of experience and scientific know-how, SRL continues to play an essential role in supporting Japan's healthcare system. As a critical healthcare infrastructure provider committed to ensuring that testing never stops, SRL continuously introduces cutting-edge diagnostic technologies and solutions from both Japan and overseas. Through these efforts, SRL remains dedicated to meeting the needs of medical institutions and patients. For more information, please visit https://www.srl-group.co.jp/english/.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits of the expanded collaboration with SRL, including improved testing efficiency, shorter sample turn-around-time and an improved testing experience for patients and health care providers; the timing and receipt of regulatory approval for local testing of BRACAnalysis Diagnostic System in Japan; the company’s intent to pursue additional regulatory approvals and reimbursement in Japan; the potential for additional precision medicine and companion diagnostic offerings in Japan; the strengthening of the company’s position in Japan; and long-term profitable growth. These forward-looking statements are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially and adversely from those anticipated. Such factors include the risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contacts
Matt Scalo
(801) 584-3532
IR@myriad.com
SRL IR/SR Dept.
+81-3-6279-0926
IR@hugp.com
Media Contacts
Andria Rosell
(385) 202-3510
PR@myriad.com
SRL Public Relations/Sustainability Dept.
+81-3-6279-0884
PR@hugp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What changes under Myriad Genetics' expanded SRL partnership in Japan?
SRL will perform all BRACAnalysis Diagnostic System laboratory processing locally in Japan, while Myriad will continue providing genetic interpretation services. Enabling local testing is subject to regulatory approval.